News & Events zu Novartis AG (NVS)NVSNovartis AG

Novartis Reports Q3 Net Sales of $14.5B

Reports Q3 net sales $14.5B vs. $13.9B last year. Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis, said: "Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU. While the del-desiran readout in DM1 was not what we had hoped, we saw evidence of clinical activity in the data and are working through the development path for this medicine. Importantly, our programs in FSHD and DMD continue to progress well. With continued momentum across the business and pipeline, we remain well on track to deliver our mid- and long-term outlook."

Core Operating Income Expected to Grow Low Single-Digit

Core operating income now expected to be in line to grow low single-digit. Previous view of decline low single-digit.

Novartis Reports Pivotal Results: Remibrutinib Significantly Reduces Relapse Rate

Novartis presented positive results from the pivotal Phase 3 REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, showing that remibrutinib, a highly selective and efficacious oral Bruton's tyrosine kinase inhibitor, demonstrated superior relapse control and a clinically meaningful delay in disease progression versus teriflunomide with no liver safety signal. The study results were presented during a late-breaking session at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, and were published simultaneously in The Lancet. Remibrutinib reduced the annualized relapse rate versus teriflunomide, the primary endpoint of both trials, with statistically significant and clinically meaningful 35.2% and 31.2% relative reduction, translating to approximately one relapse every 13 years. Remibrutinib achieved a clinically meaningful delay in disability progression, reducing the risk of 6-month confirmed disability progression by 29.2%, with nominal significance, and a consistent positive trend of 20.5% reduction in 3-month confirmed disability progression. More than 92% of patients receiving remibrutinib remained free from disease progression over 24 months as assessed by 6mCDP. In addition to the efficacy findings, remibrutinib demonstrated no liver safety signal, including no Hy's Law cases, which have been reported in other late-stage BTK inhibitor programs, Novartis stated.